-
Mashup Score: 0
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human, Measurable Residual Disease Omar Nadeem, MD 1, Sarah Nikiforow, MD, PhD 2, Kevin DeBraganca, MD 3 *,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond Hematology Disease Topics & Pathways: Combination therapy, Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Human Annemiek Broijl, PhD 1, Fredrik Schjesvold, MD, PhD 2,3, Abdel el Yaakoubi, MSc 4 *, Djamila Issa, MD PhD 5 *, Sonja Zweegman, MD, PhD 6, Kon-Siong Jie 7 *, Mario Boccadoro, MD 8, Roman Hajek 9, Bronno
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/ZO2u48x7Ux
-
-
Mashup Score: 12IgM MGUS associated with anti-MAG neuropathy: a single institution experience - PubMed - 9 day(s) ago
Anti-MAG neuropathy is a very rare form of acquired polyneuropathy associated with IgM monoclonal gammopathy of undetermined significance (MGUS). We conducted a retrospective review of 194 consecutive MGUS patients seen at the Penn State Hershey Cancer Institute. We identified six patients among 37 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
IgM MGUS associated with anti-MAG neuropathy: a single institution experience https://t.co/wu1FXj7spH #mmsm #MedTwitter @USMIRCNEWS #USMIRC #MedEd
-
-
Mashup Score: 13Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma | GSK - 11 day(s) ago
Full data to be presented at 2024 American Society of Hematology Annual Meeting in December.
Source: www.gsk.comCategories: General Medicine News, Hem/OncsTweet-
Belantamab/Vd showed OS compared to DVd! Another BCMA directed therapy showing OS over Dara based therapy! More to come next #ASH24 #mmsm #myeloma #MedTwitter @OncoAlert https://t.co/1WXfNrFA7Q
-
-
Mashup Score: 19
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care th…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
🚨 Will we soon see Belantamab back in relapse myeloma as part of a combination therapy? #mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert https://t.co/38SXWHI5Or https://t.co/0Kh72M9oWv
-
-
Mashup Score: 0Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma - 2 month(s) ago
Novel therapies have improved outcomes for multiple myeloma (MM) patients, but most ultimately relapse, making treatment decisions for relapsed/refractory MM (RRMM) patients increasingly challenging….
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/dFKpFYvSOK
-
-
Mashup Score: 9
This cross-sectional study compares medical research abstracts written by surgical trainees or senior surgeons vs abstracts generated by artificial intelligence.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
I believe that AI will replace medical writers, researchers, and possibly biostatisticians. It's possible that Pharma might not need any traditional researchers in the near future.🤷♂️ The new shape of Academia! https://t.co/vSlzxcWVxL #medtwitter #MedEd
-
-
Mashup Score: 0Drug-induced corneal deposits: an up-to-date review - 3 month(s) ago
This review assesses different clinical aspects of the various known drug-induced corneal deposits, based on the corneal layer involved (epithelium, stroma and/or endothelium), and based on the drug class. The most well-known condition caused by drug deposits is vortex keratopathy, or corneal verticillata, which is a whorl-like opacity in the corneal epithelium. Vortex keratopathy is commonly caused by certain cationic amphiphilic drugs such as amiodarone, antimalarials, suramin, tamoxifen, chlorpromazine and non-steroidal anti-inflammatory drugs. These deposits usually occur once a certain dose of the drug is reached. Most cases present with mild to moderate symptoms with minimal visual impairment. Most of these deposits resolve automatically, after months to years of drug cessation. Notably, other drug classes can cause deposits in all three layers of the cornea. Chlorpromazine, gold, rifabutin, indomethacin and tyrosine kinase inhibitors can cause stromal deposits, with reduced visu
Source: bmjophth.bmj.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/FmqSRFQHcU
-
-
Mashup Score: 7UB resident physicians set to go on strike at midnight - 3 month(s) ago
All hospitals in the Buffalo area would be impacted by the strike.
Source: www.wivb.comCategories: General Medicine News, Hem/OncsTweet-
🚨🚨 This is a right move for all residents: UB resident physicians set to go on strike at midnight #medtwiter #MedEd https://t.co/AIr2qCpngE
-
-
Mashup Score: 5Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma - 3 month(s) ago
The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug combinations are lacking, and instead, these regimens are typically compared to 3-drug backbones; limiting the ability to discern whether any additional benefit (or toxicity) is simply additive or represents a synergy (or interaction). We conducted a meta-analysis of phase 2 and phase 3 clinical trials that randomized treatment naïve NDMM patients to either a 4-drug or 3-drug induction regimen. We included 11 trials which represented 6509 unique patients. PFS for all trials in the meta-analysis was 54 months with a 4-drug induction and 8.9 months with a 3-drug induction (HR: 0.49; 95% CI: 0.45; 0.54), but there was no benefit to using a 4-drug induction that did not include an anti-CD38 antibody (PFS 4-drug 8.1 months, PFS 3-drug 8.0 months; HR 0.95; 95% CI 0.86; 1.06).
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/fiVwQQGMKP
-
https://t.co/kQKN99sKHh